John Bradley Holcomb - 23 Sep 2025 Form 4 Insider Report for MiNK Therapeutics, Inc. (INKT)

Reporting relationship: Director
Issuer ticker: INKT
Reported as of: 23 Sep 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 30 Apr 2026, 16:30:09 UTC
Next SEC filing: 03 Dec 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Austin Charette, Attorney-in-Fact for John Holcomb

Key filing fact

John Bradley Holcomb filed Form 4 for MiNK Therapeutics, Inc. (INKT) on 30 Apr 2026.

Key facts

This page summarizes John Bradley Holcomb's Form 4 filing for MiNK Therapeutics, Inc. (INKT).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 30 Apr 2026, 16:30.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002092279 Primary reporting owner

Holcomb John Bradley

Relationship: Director
Address: 149 FIFTH AVENUE, SUITE 500, NEW YORK
Signature: By: /s/ Austin Charette, Attorney-in-Fact for John Holcomb
Signature date: 30 Apr 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

INKT transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value
Shares: +4,174
Change %
Price: $0.000000^*
Shares after: 4,174
Date: 23 Sep 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,174
Exercise price: $14.92
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The Stock Options were awarded in accordance with the MiNK Therapeutics Inc. 2021 Amended and Restated Equity Incentive Plan on September 23, 2025 and will vest in three equal annual installments on each of September 23, 2026, 2027 and 2028 (provided Dr. Holcomb maintains a service relationship with the company through each such vesting date).